Abivax SA Sponsored ADR (ABVX) has released an update.
Abivax SA is advancing its combination therapy program for ulcerative colitis, revealing promising preclinical data for obefazimod in conjunction with etrasimod, showing improved disease markers in a mouse model. The company aims to develop a fixed-dose therapy that may overcome current efficacy limitations and improve long-term patient outcomes. More comprehensive results and updates are expected to be shared by the end of the year, with further clinical development anticipated.
For further insights into ABVX stock, check out TipRanks’ Stock Analysis page.
